interest in antisense technology is growing ,...im sure that there will be high interest in ANP if phase 2 trial is positive .LOVE IT especially the brutally low valuation of $ 22 million .
“2019 could be seen in years to come as the start of a new era for RNA therapeutics.”
https://wxpress.wuxiapptec.com/rna-focused-drug-development-emerging-as-a-dominant-treatment-modality-2/
Ultragenyx snags option on antisense startup GeneTx
https://www.fiercebiotech.com/biotech/ultragenyx-snags-option-antisense-startup-genetxJ&J bets billions on RNA interference..
https://www.biopharmadive.com/news/jj-bets-billions-on-rna-interference/538908/
